Analysts forecast that TG Therapeutics Inc (NASDAQ:TGTX) will report earnings of ($0.45) per share for the current quarter, Zacks reports. Three analysts have made estimates for TG Therapeutics’ earnings. The lowest EPS estimate is ($0.49) and the highest is ($0.41). TG Therapeutics reported earnings per share of ($0.46) in the same quarter last year, which indicates a positive year-over-year growth rate of 2.2%. The firm is scheduled to announce its next earnings report on Thursday, March 14th.

On average, analysts expect that TG Therapeutics will report full-year earnings of ($2.03) per share for the current fiscal year, with EPS estimates ranging from ($2.10) to ($1.98). For the next financial year, analysts forecast that the firm will post earnings of ($1.60) per share, with EPS estimates ranging from ($2.06) to ($0.96). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side analysts that follow TG Therapeutics.

TG Therapeutics (NASDAQ:TGTX) last posted its earnings results on Friday, November 9th. The biopharmaceutical company reported ($0.43) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.55) by $0.12. The firm had revenue of $0.04 million for the quarter, compared to analysts’ expectations of $0.04 million. TG Therapeutics had a negative net margin of 99,001.33% and a negative return on equity of 185.20%.

A number of equities research analysts recently commented on the stock. ValuEngine cut shares of TG Therapeutics from a “buy” rating to a “hold” rating in a report on Monday, September 17th. Raymond James cut shares of TG Therapeutics from a “strong-buy” rating to an “outperform” rating and lowered their price target for the stock from $22.00 to $12.00 in a report on Tuesday, September 25th. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 price target on shares of TG Therapeutics in a report on Monday, November 12th. Zacks Investment Research raised shares of TG Therapeutics from a “hold” rating to a “buy” rating and set a $5.75 price target on the stock in a report on Friday, November 16th. Finally, LADENBURG THALM/SH SH set a $27.00 target price on shares of TG Therapeutics and gave the company a “buy” rating in a report on Wednesday, September 26th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the company’s stock. TG Therapeutics presently has an average rating of “Buy” and a consensus price target of $18.35.

A number of hedge funds have recently modified their holdings of TGTX. RA Capital Management LLC raised its holdings in TG Therapeutics by 73.1% during the 2nd quarter. RA Capital Management LLC now owns 4,278,796 shares of the biopharmaceutical company’s stock valued at $56,266,000 after acquiring an additional 1,806,452 shares during the period. Wells Fargo & Company MN raised its holdings in TG Therapeutics by 2,148.1% during the 2nd quarter. Wells Fargo & Company MN now owns 888,768 shares of the biopharmaceutical company’s stock valued at $11,686,000 after acquiring an additional 849,233 shares during the period. BlackRock Inc. raised its holdings in TG Therapeutics by 17.4% during the 2nd quarter. BlackRock Inc. now owns 4,081,050 shares of the biopharmaceutical company’s stock valued at $53,667,000 after acquiring an additional 605,844 shares during the period. Renaissance Technologies LLC bought a new stake in TG Therapeutics during the 3rd quarter valued at $1,974,000. Finally, Opaleye Management Inc. raised its holdings in TG Therapeutics by 127.9% during the 2nd quarter. Opaleye Management Inc. now owns 625,000 shares of the biopharmaceutical company’s stock valued at $8,218,000 after acquiring an additional 350,800 shares during the period. 57.30% of the stock is currently owned by institutional investors and hedge funds.

Shares of NASDAQ:TGTX traded up $0.04 during mid-day trading on Thursday, reaching $5.04. The company had a trading volume of 1,552,400 shares, compared to its average volume of 1,348,560. The stock has a market capitalization of $414.49 million, a PE ratio of -2.64 and a beta of 1.72. TG Therapeutics has a one year low of $4.20 and a one year high of $17.35.

About TG Therapeutics

TG Therapeutics, Inc, a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases in the United States. It develops TG-1101 (ublituximab), a chimeric, glycoengineered monoclonal antibody that targets an epitope on the CD20 antigen found on the surface of B-lymphocytes developed to aid in the depletion of circulating B-cells; and TG-1101 in combination with TGR-1202 for relapsed/refractory chronic lymphocytic leukemia.

Read More: Average Daily Trade Volume – What You Need to Know

Get a free copy of the Zacks research report on TG Therapeutics (TGTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for TG Therapeutics (NASDAQ:TGTX)

Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.